Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 503 entries
Sorted by: Best Match Show Resources per page
Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells.

Experimental hematology & oncology

Cang S, Ma Y, Chiao JW, Liu D.
PMID: 24495785
Exp Hematol Oncol. 2014 Feb 05;3(1):5. doi: 10.1186/2162-3619-3-5.

Combination of phenethyl isothiocyanate (PEITC) and paclitaxel (taxol) has been shown to work synergistically to increase apoptosis and cell cycle arrest in breast cancer cells. In this report, we further explored the mechanisms for the synergistic activity of PEITC...

Cite
Cang S, Ma Y, Chiao JW, et al. Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells. Exp Hematol Oncol. 2014;3(1):5doi: 10.1186/2162-3619-3-5.
Cang, S., Ma, Y., Chiao, J. W., & Liu, D. (2014). Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells. Experimental hematology & oncology, 3(1), 5. https://doi.org/10.1186/2162-3619-3-5
Cang, Shundong, et al. "Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells." Experimental hematology & oncology vol. 3,1 (2014): 5. doi: https://doi.org/10.1186/2162-3619-3-5
Cang S, Ma Y, Chiao JW, Liu D. Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells. Exp Hematol Oncol. 2014 Feb 05;3(1):5. doi: 10.1186/2162-3619-3-5. PMID: 24495785; PMCID: PMC3927854.
Copy Download .nbib Format: NLM
The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients.

Experimental hematology & oncology

Koumarianou A, Christodoulou MI, Patapis P, Papadopoulos I, Liakata E, Giagini A, Stavropoulou A, Poulakaki N, Tountas N, Xiros N, Economopoulos T, Pectasides D, Tsitsilonis OE, Pappa V.
PMID: 24456704
Exp Hematol Oncol. 2014 Jan 23;3(1):3. doi: 10.1186/2162-3619-3-3.

BACKGROUND: The host's immune system is crucially involved in cancer development and progression. The ratio of regulatory to effector T-cells, as well as the interplay of T-cells with therapeutic agents, impact on cancer prognosis. The current study aimed to...

Cite
Koumarianou A, Christodoulou MI, Patapis P, et al. The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients. Exp Hematol Oncol. 2014;3(1):3doi: 10.1186/2162-3619-3-3.
Koumarianou, A., Christodoulou, M. I., Patapis, P., Papadopoulos, I., Liakata, E., Giagini, A., Stavropoulou, A., Poulakaki, N., Tountas, N., Xiros, N., Economopoulos, T., Pectasides, D., Tsitsilonis, O. E., & Pappa, V. (2014). The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients. Experimental hematology & oncology, 3(1), 3. https://doi.org/10.1186/2162-3619-3-3
Koumarianou, Anna, et al. "The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients." Experimental hematology & oncology vol. 3,1 (2014): 3. doi: https://doi.org/10.1186/2162-3619-3-3
Koumarianou A, Christodoulou MI, Patapis P, Papadopoulos I, Liakata E, Giagini A, Stavropoulou A, Poulakaki N, Tountas N, Xiros N, Economopoulos T, Pectasides D, Tsitsilonis OE, Pappa V. The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients. Exp Hematol Oncol. 2014 Jan 23;3(1):3. doi: 10.1186/2162-3619-3-3. PMID: 24456704; PMCID: PMC3906764.
Copy Download .nbib Format: NLM
Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma.

Experimental hematology & oncology

Wei G, Nwakuche U, Cadavid G, Ajaz A, Seiter K, Liu D.
PMID: 23210632
Exp Hematol Oncol. 2012 Mar 26;1(1):3. doi: 10.1186/2162-3619-1-3.

No abstract available.

Cite
Wei G, Nwakuche U, Cadavid G, et al. Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma. Exp Hematol Oncol. 2012;1(1):3doi: 10.1186/2162-3619-1-3.
Wei, G., Nwakuche, U., Cadavid, G., Ajaz, A., Seiter, K., & Liu, D. (2012). Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma. Experimental hematology & oncology, 1(1), 3. https://doi.org/10.1186/2162-3619-1-3
Wei, Guoqing, et al. "Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma." Experimental hematology & oncology vol. 1,1 (2012): 3. doi: https://doi.org/10.1186/2162-3619-1-3
Wei G, Nwakuche U, Cadavid G, Ajaz A, Seiter K, Liu D. Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma. Exp Hematol Oncol. 2012 Mar 26;1(1):3. doi: 10.1186/2162-3619-1-3. PMID: 23210632; PMCID: PMC3506991.
Copy Download .nbib Format: NLM
Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011.

Experimental hematology & oncology

Ali N, Adil SN, Shaikh MU, Moosajee M, Masood N.
PMID: 23210643
Exp Hematol Oncol. 2012 May 18;1(1):13. doi: 10.1186/2162-3619-1-13.

We present our initial experience of allogeneic stem cell transplant procedure performed between April 2004 and August 2011 for various haematological disorders. All patients with non-malignant and malignant haematological disorders with HLA matched donors were selected after pre-transplant workup....

Cite
Ali N, Adil SN, Shaikh MU, et al. Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011. Exp Hematol Oncol. 2012;1(1):13doi: 10.1186/2162-3619-1-13.
Ali, N., Adil, S. N., Shaikh, M. U., Moosajee, M., & Masood, N. (2012). Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011. Experimental hematology & oncology, 1(1), 13. https://doi.org/10.1186/2162-3619-1-13
Ali, Natasha, et al. "Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011." Experimental hematology & oncology vol. 1,1 (2012): 13. doi: https://doi.org/10.1186/2162-3619-1-13
Ali N, Adil SN, Shaikh MU, Moosajee M, Masood N. Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011. Exp Hematol Oncol. 2012 May 18;1(1):13. doi: 10.1186/2162-3619-1-13. PMID: 23210643; PMCID: PMC3514083.
Copy Download .nbib Format: NLM
R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma.

Experimental hematology & oncology

Mishima Y, Terui Y, Yokoyama M, Nishimura N, Sakajiri S, Ueda K, Kuboki Y, Nakano K, Suzuki K, Nara E, Tsuyama N, Takeuchi K, Oguchi M, Hatake K.
PMID: 23210663
Exp Hematol Oncol. 2012 Sep 24;1(1):30. doi: 10.1186/2162-3619-1-30.

BACKGROUND: The treatment strategy for gastric diffuse large cell lymphoma (DLBCL) has not been standardized in such as to the cycles of chemotherapy, dose of radiation, or necessity for the surgery. Although the results of CHOP or R-CHOP treatments...

Cite
Mishima Y, Terui Y, Yokoyama M, et al. R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma. Exp Hematol Oncol. 2012;1(1):30doi: 10.1186/2162-3619-1-30.
Mishima, Y., Terui, Y., Yokoyama, M., Nishimura, N., Sakajiri, S., Ueda, K., Kuboki, Y., Nakano, K., Suzuki, K., Nara, E., Tsuyama, N., Takeuchi, K., Oguchi, M., & Hatake, K. (2012). R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma. Experimental hematology & oncology, 1(1), 30. https://doi.org/10.1186/2162-3619-1-30
Mishima, Yuko, et al. "R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma." Experimental hematology & oncology vol. 1,1 (2012): 30. doi: https://doi.org/10.1186/2162-3619-1-30
Mishima Y, Terui Y, Yokoyama M, Nishimura N, Sakajiri S, Ueda K, Kuboki Y, Nakano K, Suzuki K, Nara E, Tsuyama N, Takeuchi K, Oguchi M, Hatake K. R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma. Exp Hematol Oncol. 2012 Sep 24;1(1):30. doi: 10.1186/2162-3619-1-30. PMID: 23210663; PMCID: PMC3514105.
Copy Download .nbib Format: NLM
JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines.

Experimental hematology & oncology

Zhao W, Du Y, Ho WT, Fu X, Zhao ZJ.
PMID: 23210734
Exp Hematol Oncol. 2012 Jun 21;1(1):15. doi: 10.1186/2162-3619-1-15.

BACKGROUND: JAK2V617F, a gain-of-function mutant form of tyrosine kinase JAK2, is found in the majority of patients with Ph- myeloproliferative neoplasms (MPNs), a group of chronic hematological diseases that often lead to acute leukemia. The current study is intended...

Cite
Zhao W, Du Y, Ho WT, et al. JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines. Exp Hematol Oncol. 2012;1(1):15doi: 10.1186/2162-3619-1-15.
Zhao, W., Du, Y., Ho, W. T., Fu, X., & Zhao, Z. J. (2012). JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines. Experimental hematology & oncology, 1(1), 15. https://doi.org/10.1186/2162-3619-1-15
Zhao, Wanke, et al. "JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines." Experimental hematology & oncology vol. 1,1 (2012): 15. doi: https://doi.org/10.1186/2162-3619-1-15
Zhao W, Du Y, Ho WT, Fu X, Zhao ZJ. JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines. Exp Hematol Oncol. 2012 Jun 21;1(1):15. doi: 10.1186/2162-3619-1-15. PMID: 23210734; PMCID: PMC3514099.
Copy Download .nbib Format: NLM
Acute myeloid leukemia with t(7;21)(p22;q22) and 5q deletion: a case report and literature review.

Experimental hematology & oncology

Ji J, Loo E, Pullarkat S, Yang L, Tirado CA.
PMID: 24646765
Exp Hematol Oncol. 2014 Mar 19;3:8. doi: 10.1186/2162-3619-3-8. eCollection 2014.

The gene RUNX1 at chromosome 21q22 encodes the alpha subunit of Core binding factor (CBF), a heterodimeric transcription factor involved in the development of normal hematopoiesis. Translocations of RUNX1 are seen in several types of leukemia with at least...

Cite
Ji J, Loo E, Pullarkat S, et al. Acute myeloid leukemia with t(7;21)(p22;q22) and 5q deletion: a case report and literature review. Exp Hematol Oncol. 2014;3:8doi: 10.1186/2162-3619-3-8.
Ji, J., Loo, E., Pullarkat, S., Yang, L., & Tirado, C. A. (2014). Acute myeloid leukemia with t(7;21)(p22;q22) and 5q deletion: a case report and literature review. Experimental hematology & oncology, 38. https://doi.org/10.1186/2162-3619-3-8
Ji, Jianling, et al. "Acute myeloid leukemia with t(7;21)(p22;q22) and 5q deletion: a case report and literature review." Experimental hematology & oncology vol. 3 (2014): 8. doi: https://doi.org/10.1186/2162-3619-3-8
Ji J, Loo E, Pullarkat S, Yang L, Tirado CA. Acute myeloid leukemia with t(7;21)(p22;q22) and 5q deletion: a case report and literature review. Exp Hematol Oncol. 2014 Mar 19;3:8. doi: 10.1186/2162-3619-3-8. eCollection 2014. PMID: 24646765; PMCID: PMC4012275.
Copy Download .nbib Format: NLM
Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis.

Experimental hematology & oncology

Smith BD, Beach CL, Mahmoud D, Weber L, Henk HJ.
PMID: 24666795
Exp Hematol Oncol. 2014 Mar 25;3(1):10. doi: 10.1186/2162-3619-3-10.

BACKGROUND: This study examined patient outcomes using real world data for acute myeloid leukemia (AML) patients initiating treatment.METHODS: A retrospective, administrative claims-based, comparative analysis was developed to study outcomes for AML patients initiating treatment with decitabine or azacitidine between...

Cite
Smith BD, Beach CL, Mahmoud D, et al. Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis. Exp Hematol Oncol. 2014;3(1):10doi: 10.1186/2162-3619-3-10.
Smith, B. D., Beach, C. L., Mahmoud, D., Weber, L., & Henk, H. J. (2014). Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis. Experimental hematology & oncology, 3(1), 10. https://doi.org/10.1186/2162-3619-3-10
Smith, B Douglas, et al. "Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis." Experimental hematology & oncology vol. 3,1 (2014): 10. doi: https://doi.org/10.1186/2162-3619-3-10
Smith BD, Beach CL, Mahmoud D, Weber L, Henk HJ. Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis. Exp Hematol Oncol. 2014 Mar 25;3(1):10. doi: 10.1186/2162-3619-3-10. PMID: 24666795; PMCID: PMC3994315.
Copy Download .nbib Format: NLM
Mantle cell lymphoma and its management: where are we now?.

Experimental hematology & oncology

Ladha A, Zhao J, Epner EM, Pu JJ.
PMID: 30733891
Exp Hematol Oncol. 2019 Jan 30;8:2. doi: 10.1186/s40164-019-0126-0. eCollection 2019.

Mantle cell lymphoma is a relatively new recognized hematological malignant disease, comprising of 2.5-6% non-Hodgkin's lymphomas. The complexity of its clinical presentations (nodular pattern, diffuse pattern, and blastoid variant), variety in disease progression, and treatment response, make this disease...

Cite
Ladha A, Zhao J, Epner EM, et al. Mantle cell lymphoma and its management: where are we now?. Exp Hematol Oncol. 2019;8:2doi: 10.1186/s40164-019-0126-0.
Ladha, A., Zhao, J., Epner, E. M., & Pu, J. J. (2019). Mantle cell lymphoma and its management: where are we now?. Experimental hematology & oncology, 82. https://doi.org/10.1186/s40164-019-0126-0
Ladha, Abdullah, et al. "Mantle cell lymphoma and its management: where are we now?." Experimental hematology & oncology vol. 8 (2019): 2. doi: https://doi.org/10.1186/s40164-019-0126-0
Ladha A, Zhao J, Epner EM, Pu JJ. Mantle cell lymphoma and its management: where are we now?. Exp Hematol Oncol. 2019 Jan 30;8:2. doi: 10.1186/s40164-019-0126-0. eCollection 2019. PMID: 30733891; PMCID: PMC6354396.
Copy Download .nbib Format: NLM
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide.

Experimental hematology & oncology

Albertsson-Lindblad A, Freiburghaus C, Jerkeman M, Ek S.
PMID: 31406628
Exp Hematol Oncol. 2019 Aug 06;8:16. doi: 10.1186/s40164-019-0141-1. eCollection 2019.

BACKGROUND: The Bruton's Tyrosine Kinase (BTK)-inhibitor ibrutinib is highly active in mantle cell lymphoma (MCL) but may inhibit response to anti-CD20 antibody as previously shown in CLL models. We investigated how antibody-dependent cellular cytotoxicity (ADCC) induced by type I/II...

Cite
Albertsson-Lindblad A, Freiburghaus C, Jerkeman M, et al. Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide. Exp Hematol Oncol. 2019;8:16doi: 10.1186/s40164-019-0141-1.
Albertsson-Lindblad, A., Freiburghaus, C., Jerkeman, M., & Ek, S. (2019). Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide. Experimental hematology & oncology, 816. https://doi.org/10.1186/s40164-019-0141-1
Albertsson-Lindblad, Alexandra, et al. "Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide." Experimental hematology & oncology vol. 8 (2019): 16. doi: https://doi.org/10.1186/s40164-019-0141-1
Albertsson-Lindblad A, Freiburghaus C, Jerkeman M, Ek S. Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide. Exp Hematol Oncol. 2019 Aug 06;8:16. doi: 10.1186/s40164-019-0141-1. eCollection 2019. PMID: 31406628; PMCID: PMC6685275.
Copy Download .nbib Format: NLM
Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy.

Experimental hematology & oncology

Desai K, Misra P, Kher S, Shah N.
PMID: 30202638
Exp Hematol Oncol. 2018 Sep 06;7:22. doi: 10.1186/s40164-018-0114-9. eCollection 2018.

BACKGROUND: Chemotherapy-induced neutropenia is a common result of myelosuppressive chemotherapy treatment. Infections such as febrile neutropenia (FN) are sensitive to the duration of neutropenia as well as the depth of absolute neutrophil count (ANC) at nadir. Filgrastim, a granulocyte...

Cite
Desai K, Misra P, Kher S, et al. Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy. Exp Hematol Oncol. 2018;7:22doi: 10.1186/s40164-018-0114-9.
Desai, K., Misra, P., Kher, S., & Shah, N. (2018). Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy. Experimental hematology & oncology, 722. https://doi.org/10.1186/s40164-018-0114-9
Desai, Kalpna, et al. "Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy." Experimental hematology & oncology vol. 7 (2018): 22. doi: https://doi.org/10.1186/s40164-018-0114-9
Desai K, Misra P, Kher S, Shah N. Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy. Exp Hematol Oncol. 2018 Sep 06;7:22. doi: 10.1186/s40164-018-0114-9. eCollection 2018. PMID: 30202638; PMCID: PMC6127997.
Copy Download .nbib Format: NLM
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment.

Experimental hematology & oncology

Yu S, Liu Q, Han X, Qin S, Zhao W, Li A, Wu K.
PMID: 29209558
Exp Hematol Oncol. 2017 Nov 28;6:31. doi: 10.1186/s40164-017-0091-4. eCollection 2017.

HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for the treatment of HER2 positive metastatic breast cancer. The...

Cite
Yu S, Liu Q, Han X, et al. Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. Exp Hematol Oncol. 2017;6:31doi: 10.1186/s40164-017-0091-4.
Yu, S., Liu, Q., Han, X., Qin, S., Zhao, W., Li, A., & Wu, K. (2017). Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. Experimental hematology & oncology, 631. https://doi.org/10.1186/s40164-017-0091-4
Yu, Shengnan, et al. "Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment." Experimental hematology & oncology vol. 6 (2017): 31. doi: https://doi.org/10.1186/s40164-017-0091-4
Yu S, Liu Q, Han X, Qin S, Zhao W, Li A, Wu K. Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. Exp Hematol Oncol. 2017 Nov 28;6:31. doi: 10.1186/s40164-017-0091-4. eCollection 2017. PMID: 29209558; PMCID: PMC5704598.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 503 entries